A highly accomplished and esteemed researcher and doctor, Mikhail (Misha) V. Blagosklonny, MD, Ph.D., is based in Buffalo, New York. There, he holds the title of Professor of Oncology at the Roswell Park Center Institute. Dr. Mikhail Blagosklonny has an admirable list of achievements cen-tered around his passion for finding links and similarities in the pathways between cancer and aging. His journey to earning the respected title at Roswell Park was a work in the making for several years involving a lengthy education and abundance of work experience.
After earning his M.D. in internal medicine and his Ph.D. in experimental medicine and cardiolo-gy from the prestigious First Pavlov State Medical University in St. Petersburg, Russia, Dr. Mikhail Blagosklonny worked as an assistant professor in New York Medical College before earning his next appointment to work as a senior scientist. Based in Albany, New York, Blagosklonny worked at the Ordway Research Institute, which he held until being given the position of Profes-sor of Oncology at the Roswell Park Cancer Institute in Buffalo, New York.
Dr. Blagosklonny’s interests are broadly based on cancer and aging, specifically involving the molecular and cellular biology of the study of oncogenes and tumor suppressors. He focuses on signal transduction, separation involving apoptosis, mitosis, and the cell cycle, and anticancer therapies and preventative strategies for normal cells. Starting with the study of cancer, Mikhail Blagosklonny has also used these same approaches to study aging and age-related diseases; and the results have been extraordinary as he has helped reveal ant-aging drugs such as rapamycin. Studying drugs such as rapamycin has prompted Blagosklonny to propose cancer-related thera-pies for normal cells in protecting them from aging. This area of study is scientifically termed bi-ogerontology. Blagosklonny has hypothesized rapamycin as a possible treatment for extending the longevity of life. Since the release of the drug, Blagosklonny has been quite a vocal advocate about its use and benefits for the study of longevity research.
Finally, Dr. Blagosklonny has also been deeply involved in publishing articles in journals all over the world. Mikhail Blagosklonny has published over 300 articles, reviews and book chapters for journals like Can-cer Research, The American Journal of Pathology, Aging, Cancer Research, PLOS ONE, Inter-national Journal of Cancer, Cancer Research, Autophagy, and Cancer Biology & Therapy, serv-ing as the Founding Editor, Editor-in-Chief, Co-editor, and Co-founder. His publishings revolve around subjects that delve into hyperfunction theory of aging, cell psychotherapy and chemo-therapeutic engineering, and anti-cancer approaches.